Literature DB >> 15578508

Serum markers detect the presence of liver fibrosis: a cohort study.

William M C Rosenberg1, Michael Voelker, Robert Thiel, Michael Becka, Alastair Burt, Detlef Schuppan, Stefan Hubscher, Tania Roskams, Massimo Pinzani, Michael J P Arthur.   

Abstract

BACKGROUND & AIMS: Histologic examination of a liver biopsy specimen is regarded as the reference standard for detecting liver fibrosis. Biopsy can be painful and hazardous, and assessment is subjective and prone to sampling error. We developed a panel of sensitive automated immunoassays to detect matrix constituents and mediators of matrix remodeling in serum to evaluate their performance in the detection of liver fibrosis.
METHODS: In an international multicenter cohort study, serum levels of 9 surrogate markers of liver fibrosis were compared with fibrosis stage in liver biopsy specimens obtained from 1021 subjects with chronic liver disease. Discriminant analysis of a test set of samples was used to identify an algorithm combining age, hyaluronic acid, amino-terminal propeptide of type III collagen, and tissue inhibitor of matrix metalloproteinase 1 that was subsequently evaluated using a validation set of biopsy specimens and serum samples.
RESULTS: The algorithm detected fibrosis (sensitivity, 90%) and accurately detected the absence of fibrosis (negative predictive value for significant fibrosis, 92%; area under the curve of a receiver operating characteristic plot, .804; standard error, .02; P < .0001; 95% confidence interval, .758-.851). Performance was excellent for alcoholic liver disease and nonalcoholic fatty liver disease. The algorithm performed equally well in comparison with each of the pathologists. In contrast, pathologists' agreement over histologic scores ranged from very good to moderate (kappa = .97-.46).
CONCLUSIONS: Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific, and reproducible, suggesting they may be used in conjunction with liver biopsy to assess a range of chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578508     DOI: 10.1053/j.gastro.2004.08.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  253 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

3.  Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics.

Authors:  Vivekananda Shetty; Pooja Jain; Zacharie Nickens; Gomathinayagam Sinnathamby; Anand Mehta; Ramila Philip
Journal:  OMICS       Date:  2011-10

4.  Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases.

Authors:  Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

5.  Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C.

Authors:  Jae Youn Cheong; Soon Ho Um; Yeon Seok Seo; Dong Joon Kim; Seong Gyu Hwang; Youn Jae Lee; Mong Cho; Jin Mo Yang; Young Bae Kim; Young Nyun Park; Sung Won Cho
Journal:  Dig Dis Sci       Date:  2010-06-29       Impact factor: 3.199

6.  A new index for non-invasive assessment of liver fibrosis.

Authors:  Naohiro Ichino; Keisuke Osakabe; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Yuko Arima; Hiroaki Shimazaki; Koji Suzuki; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

7.  Detection of novel biomarkers of liver cirrhosis by proteomic analysis.

Authors:  Christian Mölleken; Barbara Sitek; Corinna Henkel; Gereon Poschmann; Bence Sipos; Sebastian Wiese; Bettina Warscheid; Christoph Broelsch; Markus Reiser; Scott L Friedman; Ida Tornøe; Anders Schlosser; Günter Klöppel; Wolff Schmiegel; Helmut E Meyer; Uffe Holmskov; Kai Stühler
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.

Authors:  Keyur Patel; Katja S Remlinger; Terence G Walker; Peter Leitner; Joseph E Lucas; Stephen D Gardner; John G McHutchison; Will Irving; Indra Neil Guha
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-09       Impact factor: 11.382

9.  Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.

Authors:  Dalia Omran; Ayman Yosry; Samar K Darweesh; Mohammed M Nabeel; Mohammed El-Beshlawey; Sameh Saif; Azza Fared; Mohamed Hassany; Rania A Zayed
Journal:  Clin Exp Med       Date:  2017-05-31       Impact factor: 3.984

Review 10.  Non-invasive diagnosis of advanced fibrosis and cirrhosis.

Authors:  Suraj Sharma; Korosh Khalili; Geoffrey Christopher Nguyen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.